Novartis’ CAR-T Cell Therapy Tisagenlecleucel Shows Durable Efficacy in Pediatric and Young Adult ALL

August 17, 2026

CancerNetwork USA

Overview

Novartis’ CAR-T cell therapy, tisagenlecleucel (Kymriah), continues to demonstrate durable efficacy and safety in pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). Long-term follow-up data reveal that a significant proportion of treated patients maintain sustained responses, contributing to improved overall survival. These results underscore tisagenlecleucel’s potential as a curative option for ALL patients who previously had limited treatment avenues.

In Depth

Key Findings

Novartis’ Chimeric Antigen Receptor (CAR) T-cell therapy, tisagenlecleucel (marketed as Kymriah), has consistently demonstrated durable efficacy and a favorable safety profile in pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). Recent long-term follow-up data indicate that a substantial number of treated patients maintain sustained responses, significantly contributing to extended overall survival. This outcome strongly supports the potential of tisagenlecleucel to become a new standard of care for ALL patients who historically faced dismal prognoses with conventional treatments.

Technical and Clinical Details

Tisagenlecleucel is an autologous CAR-T cell therapy, meaning it involves collecting a patient’s own T-cells, genetically engineering them ex vivo to express a CAR that specifically recognizes and targets the CD19 antigen on cancer cells, and then reinfusing them back into the patient. Since its FDA approval in 2017, this therapy has provided revolutionary treatment outcomes for patients with refractory ALL. The reported long-term follow-up data show that overall survival rates exceeding 50% have been achieved in cohorts of treated pediatric and young adult patients after more than five years. Furthermore, approximately 70% of patients who achieved a complete response (CR) or complete response with incomplete hematologic recovery (CRi) have maintained durable responses post-treatment. Regarding the safety profile, serious adverse events such as cytokine release syndrome (CRS) and neurotoxicity (ICANS), which were initial concerns, are now largely manageable with appropriate mitigation strategies. These results clearly demonstrate the ability of a single-dose cellular therapy to provide sustained disease control over extended periods, reaffirming tisagenlecleucel’s invaluable role in ALL treatment.

Background and Industry Context

Acute Lymphoblastic Leukemia (ALL) is the most common childhood cancer, and relapsed or refractory ALL historically had an extremely poor prognosis, being very difficult to treat with conventional chemotherapy or hematopoietic stem cell transplantation. The advent of tisagenlecleucel brought a significant transformation to this unmet medical need, offering new hope to patients with refractory ALL. Since its FDA approval, numerous CAR-T cell therapies have been developed, fundamentally changing the landscape of hematologic cancer treatment. However, long-term efficacy and safety data for these therapies are still being gathered. The current long-term follow-up results for tisagenlecleucel provide strong evidence that CAR-T cell therapy can offer not just short-term responses but also potentially curative outcomes for a subset of patients. This will further accelerate progress in the broader field of cellular immunotherapy and encourage research into its application in other hematologic and solid tumors.

Strategic Significance and Outlook

The long-term efficacy data for tisagenlecleucel in pediatric and young adult ALL patients solidifies its integration as a deep component of the standard of care for ALL treatment. Future research will focus on identifying predictors of treatment response and further optimizing the early identification and management of side effects. Additionally, elucidating mechanisms of resistance to tisagenlecleucel and developing combination therapies or next-generation CAR-T cell therapies to overcome them will be crucial. This success story strongly suggests the potential for other genetically engineered cell therapies to provide similar long-term benefits across various intractable cancers and autoimmune diseases. As a pioneer demonstrating the power of cellular immunotherapy, tisagenlecleucel will continue to contribute to saving lives and improving the quality of life for many patients.

Source: https://www.cancernetwork.com/view/tisagenlecleucel-shows-durable-efficacy-in-pediatric-young-adult-all

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.